Sook Wah Yee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1495764/publications.pdf

Version: 2024-02-01

66 papers	6,390 citations	126907 33 h-index	128289 60 g-index
69 all docs	69 docs citations	69 times ranked	7899 citing authors

#	Article	IF	Citations
1	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
2	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3. Pharmaceutical Research, 2022, 39, 1599-1613.	3.5	13
3	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
4	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673â€“2682. Diabetes Care, 2022, 45, e82-e83.	8.6	0
5	New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2022, 112, 540-561.	4.7	16
6	The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. AAPS Journal, 2021, 23, 35.	4.4	2
7	Drugs in COVIDâ€19 Clinical Trials: Predicting Transporterâ€Mediated Drugâ€Drug Interactions Using In Vitro Assays and Realâ€World Data. Clinical Pharmacology and Therapeutics, 2021, 110, 108-122.	4.7	16
8	Genomewide Association Studies in Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2021, 110, 637-648.	4.7	38
9	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care, 2021, 44, 2673-2682.	8.6	23
10	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2020, 107, 96-101.	4.7	6
11	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. FASEB Journal, 2020, 34, 15734-15752.	0.5	21
12	Synthesis, Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols. Pharmaceuticals, 2020, 13, 186.	3.8	12
13	GenEpi: gene-based epistasis discovery using machine learning. BMC Bioinformatics, 2020, 21, 68.	2.6	25
14	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. PLoS Genetics, 2019, 15, e1008208.	3.5	23
15	Unveiling the Genetic Architecture of Human Disease for Precision Medicine. Clinical and Translational Science, 2019, 12, 3-5.	3.1	3
16	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drugâ€“Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. Clinical and Translational Science, 2019, 12, 388-399.	3.1	53
17	Genomeâ€Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clinical Pharmacology and Therapeutics, 2019, 106, 623-631.	4.7	23
18	Functional and structural analysis of rare SLC2A2 variants associated with Fanconiâ€Bickel syndrome and metabolic traits. Human Mutation, 2019, 40, 983-995.	2.5	13

#	Article	IF	Citations
19	Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. PLoS Biology, 2019, 17, e2006571.	5.6	41
20	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 803-817.	4.7	99
21	Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes, 2018, 67, 1428-1440.	0.6	32
22	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. Molecular Pharmacology, 2018, 94, 689-699.	2.3	40
23	Pharmacogenetics of Antidiabetic Drugs. Advances in Pharmacology, 2018, 83, 361-389.	2.0	12
24	Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLoS Biology, 2018, 16, e2002907.	5.6	45
25	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1;) Tj ETQq1 1 0.784314 rgBT /Overl	6.4	58
26	Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. Journal of Chemical Information and Modeling, 2017, 57, 1402-1413.	5.4	23
27	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nature Reviews Drug Discovery, 2017, 16, 70-70.	46.4	80
28	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Frontiers in Pharmacology, 2016, 7, 135.	3.5	28
29	Pharmacogenetics of Metformin. , 2016, , 463-481.		0
30	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	21.4	165
31	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. Drug Metabolism and Disposition, 2016, 44, 356-364.	3.3	54
32	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clinical Pharmacokinetics, 2016, 55, 711-721.	3.5	47
33	Genomic Characterization of Metformin Hepatic Response. PLoS Genetics, 2016, 12, e1006449.	3.5	41
34	OCT1 in hepatic steatosis and thiamine disposition. Cell Cycle, 2015, 14, 283-284.	2.6	15
35	Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin. Molecular Pharmacology, 2015, 88, 75-83.	2.3	88
36	SLC transporters as therapeutic targets: emerging opportunities. Nature Reviews Drug Discovery, 2015, 14, 543-560.	46.4	584

#	Article	IF	Citations
37	Prediction and validation of enzyme and transporter off-targets for metformin. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 463-475.	1.8	37
38	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics, 2015, 12, 4301-4310.	4.6	79
39	A genome-wide association study of bronchodilator response in Latinos implicates rare variants. Journal of Allergy and Clinical Immunology, 2014, 133, 370-378.e15.	2.9	105
40	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9983-9988.	7.1	203
41	Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. Journal of Human Genetics, 2013, 58, 353-361.	2.3	38
42	Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8). Journal of Pharmaceutical Sciences, 2013, 102, 3451-3457.	3.3	47
43	The role of ATM in response to metformin treatment and activation of AMPK. Nature Genetics, 2012, 44, 359-360.	21.4	46
44	Pharmacogene regulatory elements: from discovery to applications. Genome Medicine, 2012, 4, 45.	8.2	18
45	Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.. Blood, 2012, 120, 2548-2548.	1.4	0
46	SLC19A1 pharmacogenomics summary. Pharmacogenetics and Genomics, 2010, 20, 708-715.	1.5	28
47	Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides. Bioorganic and Medicinal Chemistry, 2010, 18, 4939-4946.	3.0	19
48	Comparison of human solute carriers. Protein Science, 2010, 19, 412-428.	7.6	99
49	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	46.4	2,886
50	Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue. Molecular Cancer Therapeutics, 2010, 9, 1058-1069.	4.1	74
51	Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics, 2010, 11, 475-479.	1.3	49
52	Functional Genetic Variation in the Basal Promoter of the Organic Cation/Carnitine Transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 262-271.	2.5	38
53	Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenetics and Genomics, 2009, 19, 497-504.	1.5	202
54	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics Journal, 2009, 9, 127-136.	2.0	94

#	Article	IF	Citations
55	Identification and Characterization of Proximal Promoter Polymorphisms in the Human Concentrative Nucleoside Transporter 2 (SLC28A2). Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 699-707.	2.5	30
56	Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenetics and Genomics, 2009, 19, 770-780.	1.5	56
57	Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation. PLoS ONE, 2009, 4, e6942.	2.5	34
58	Organic Anion Transporter 2 (SLC22A7) Is a Facilitative Transporter of cGMP. Molecular Pharmacology, 2008, 73, 1151-1158.	2.3	103
59	Potent CYP19 (Aromatase) 1-[(Benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole Inhibitors:Â Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2006, 49, 1016-1022.	6.4	79
60	Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2006, 98, 228-235.	2.5	42
61	Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles. Bioorganic and Medicinal Chemistry, 2006, 14, 3643-3653.	3.0	37
62	Synthesis and CYP24 Inhibitory Activity of 2-Substituted-3,4-dihydro-2H-naphthalen-1-one (Tetralone) Derivatives.. ChemInform, 2005, 36, no.	0.0	0
63	Synthesis and antimycobacterial activity of 7-O-substituted-4-methyl-2H-2-chromenone derivatives vs Mycobacterium tuberculosis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 109-113.	5.2	10
64	Novel Tetralone-Derived Retinoic Acid Metabolism Blocking Agents:â€‰ Synthesis and in Vitro Evaluation with Liver Microsomal and MCF-7 CYP26A1 Cell Assays. Journal of Medicinal Chemistry, 2005, 48, 7123-7131.	6.4	41
65	Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5651-5654.	2.2	32
66	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene <i>SLCO1B1</i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. SSRN Electronic Journal, 0, , .	0.4	0